CPH:NOVO-B 26 November 2025

Novo Nordisk shares fall after ZEUS trial disappointment highlights 94% sales reliance

Shares of Novo Nordisk A/S dropped significantly on Friday after the ZEUS trial found minimal cardiovascular benefit from ziltivekimab. The decline in U.S. trading wiped out approximately $20.5 billion in market capitalisation.

31 July 2026

CPH:NOVO-B·Earnings·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk (CPH:NOVO-B) rises, but volume stays light ahead of August results

Novo Nordisk A/S finished the week with a smaller rally than the rest of the Danish market. B shares closed Friday at DKK 326.90, dropping 1.54% on the day but still up 2.8% for the week. The OMX Copenhagen 25 gained 5.5% in the same period, so the stock lagged the benchmark by about 2.6 percentage points. Novo’s Friday volume hit 2.58 million shares, or 45% of its 65-day average, according to MarketWatch. For the week, turnover was 19.23 million shares, down from 25.66 million a week earlier. Investing.com reported the OMXC25 at 1,899.12 on Friday, up from 1,800.88 the previous week.

5 July 2026

CPH:NOVO-B·Earnings Reports·Pharmaceuticals·Stock Market

Novo Nordisk (CPH:NOVO-B) edges lower as Wegovy gains checked by Medicare limits

Novo Nordisk A/S slipped in late morning Friday in Copenhagen, trailing the local blue-chip index. Traders weighed the first U.S. Medicare obesity coverage route for Wegovy, testing the price.

3 July 2026

CPH:NOVO-B·Pharmaceuticals·Stock Market

Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk A/S stock is staging a sharp rebound today, 26 November 2025, as investors digest a trio of major developments: an FDA filing for a higher-dose version of its blockbuster obesity drug Wegovy, clarity on steep—but largely expected—Medicare price cuts for Ozempic and Wegovy, and fresh enthusiasm around its next‑generation obesity candidate amycretin.

26 November 2025

CPH:NOVO-B·NYSE:NVO·Pharmaceuticals·Stock Market